Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ERBB2 amplification, PR positive status confers therapeutic sensitivity to Neratinib in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.